had posterior scleritis. There was a slight predominance of women (55%) and unilateral disease (53%). Mean age at presentation was 51 years (range 12e82 years). Secondary ocular complications were observed in 78% of patients, including anterior uveitis in 25% and increased intraocular pressure in 40%. Investigation revealed a systemic disease association in 24 patients (29%), including six patients (7.2%) with tuberculosis and 18 patients (22%) with rheumatologic disease. Thirty-five patients (42%) received systemic corticosteroid treatment and 19 patients (23%) received immunosuppressive agents. All 17 patients with necrotising anterior scleritis or posterior scleritis were treated with oral corticosteroids and/or immunosuppressive drugs. Visual outcomes were generally good; however, poorer outcomes were observed in eyes with necrotising scleritis, mostly due to corneal ulceration or corneal opacification. Conclusions A systemic disease association was identified in 29% of Japanese patients with scleritis. Roughly one-half of patients received oral corticosteroids and/or immunosuppressive drugs to control inflammation, with generally good visual outcomes.
Scleritis is a painful, often chronic, and potentially sight-threatening disorder. 1 2 According to the Watson classification system, scleritis may be divided into anterior and posterior types. 3 Anterior scleritis may be further subdivided into diffuse, nodular and necrotising types. 3 Eyes with scleritis may develop a wide range of secondary ocular complications such as scleral thinning, scleral perforation, corneal ulceration, anterior uveitis, raised intraocular pressure, cataract, exudative retinal detachment and optic disc oedema. 1 3 In particular, necrotising scleritis has been more frequently associated with ocular complications 3 4 as well as systemic rheumatologic diseases such as rheumatoid arthritis, Wegener 's granulomatosis and relapsing polychondritis. 4e6 Systemic agents used to treat severe or refractory disease include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and immunosuppressive agents such as azathioprine, ciclosporin, methotrexate, cyclophosphamide and mycophenolate mofetil.
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Previous surveys from the USA and Europe have reported the clinical features and systemic associations in patients with scleritis 3e5 10 ; however, there are few publications involving Asian populations. 12 13 In this study, we investigated the clinical features, associated systemic diseases, treatment and visual outcomes of Japanese patients with scleritis.
METHODS
We performed a retrospective review of the medical records of 83 patients with scleritis who presented to the Ocular Inflammation Service at the Kyorin Eye Center, Kyorin University Hospital in Tokyo, Japan, between January 1998 and December 2008. The data collected included information such as age at diagnosis, gender, anatomic location of inflammation, ocular complications, associated systemic disease, use of topical and/or systemic treatments, visual outcomes and adverse events. The Watson system was used to classify type of scleritis, 3 with the diagnosis of posterior scleritis confirmed by ultrasonography and/or CT of the orbit.
14 This study was conducted in accordance with the tenets of the Declaration of Helsinki, and was deemed by the Kyorin University Hospital Research Ethics Committee not to require institutional review board approval.
The diagnosis of scleritis was based on detailed clinical history, extensive review of systems, complete ophthalmologic examination and ocular inflammatory disease-directed laboratory testing when deemed necessary. Laboratory testing included blood and urine tests, chest x ray, electrocardiogram and tuberculin skin testing (TST, 0.05 mg purified protein derivative in 0.1 ml, equivalent to 2.5 tuberculin units). Blood tests included complete blood count and white cell differential, glucose, acute phase reactants (erythrocyte sedimentation rate and C-reactive protein), liver function tests, serum creatinine, angiotensin-converting enzyme and fluorescent treponemal antibody. Associated systemic disease was diagnosed based on the results of compatible history, clinical features and laboratory data, often in consultation with rheumatology and infectious disease specialists.
The TST was judged to be positive for induration of 10 mm or greater. 15 If patients had a positive TST result, anti-tuberculous glycolipid antibody testing or the IFNg release assay, QuantiFERON-TB 2G (QFT; Cellestis, Carnegie, Australia) was generally performed to further support a diagnosis of tuberculosis scleritis. Patients in which tuberculosis treatment was initiated also had to have no other identifiable cause for their ocular inflammation.
All patients had active inflammation and therefore were treated with topical and/or systemic corticosteroids depending on the severity, location and chronicity of the inflammatory process, as well as the risk of visual loss and/or ocular complications. Indications for the use of immunosuppressive drugs included failure to adequately respond to oral corticosteroid monotherapy, the development of corticosteroid adverse effects, recurrence of inflammation with corticosteroid tapering, the need for long-term immunosuppression predicted, and associated systemic rheumatologic disease. The most frequently used immunosuppressive agent was methotrexate, usually started at a weekly oral dose of 4 mg and gradually increased by 2 mg/ week according to clinical response, adverse effects and corticosteroid-sparing efficacy. Folate was administered concomitantly in patients receiving methotrexate to reduce bone marrow suppression. Corticosteroids were tapered after initiation of methotrexate treatment and stopped whenever possible. Some patients with a history of diabetes mellitus were started on methotrexate as the first-line systemic agent. Control of inflammation was defined as the absence of active inflammation with a prednisolone dose of #5 mg daily, or tapering of the prednisolone dose to #5 mg daily while on methotrexate treatment.
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RESULTS
Demographic and clinical characteristics of all patients included in this study are summarised in table 1. Of the 83 patients with scleritis, 46 (55%) were women and 37 (45%) were men, with an overall mean age of 51.1 years (range 12e82 years). A slight majority (44 patients, 53%) had unilateral disease, with the remainder showing findings of scleritis in both eyes. The mean follow-up period was 32.0 (33.6) months (range 1e134 months).
Diffuse anterior (57 patients) was the most common type of scleritis observed in our study population, followed by nodular anterior (9 patients), posterior (9 patients) and necrotising anterior scleritis (8 patients). The mean age at presentation was oldest for patients with necrotising anterior scleritis compared to patients with other types of scleritis (mean age 61.9 years for necrotising anterior, 51.3 years for diffuse anterior, 46.8 years for posterior and 43.9 years for nodular anterior).
One or more ocular complications were observed in 78% of all patients either at presentation or during the follow-up period.
By type, ocular complications were present or developed in 44% of patients with nodular anterior scleritis, 77% of patients with diffuse anterior scleritis and 100% of patients with either necrotising anterior or posterior scleritis. The single most common complication was elevated intraocular pressure, occurring in 39.8% of all patients, with highest rates in patients with either diffuse anterior (40.3%) or necrotising anterior scleritis (75.0%). Other common anterior segment complications included anterior uveitis, scleral thinning and cataract, seen in 25.3%, 20.5% and 18.1% of all patients, respectively. Marginal corneal ulceration was most commonly observed in eyes with necrotising anterior scleritis (12.5%). Excluding anterior uveitis, rates for all anterior segment complications were highest in patients with necrotising anterior scleritis.
The posterior segment complications of exudative retinal detachment and optic disc oedema were most commonly observed in patients with posterior scleritis. In particular, exudative retinal detachment was observed in 77.8% of patients with posterior scleritis, but was also seen in 1 patient with necrotising anterior scleritis who had a component of posterior scleritis that was confirmed using ultrasonography. Cystoid macular oedema was observed in 25% of patients with necrotising anterior scleritis. Posterior segment complications were rare in patients with diffuse or nodular anterior scleritis.
Diagnostic investigation revealed a positive TST result in 13 of 63 patients (20.6%) who underwent TST testing. The TSTpositive rate was highest in patients with nodular anterior scleritis (55.5%) compared to patients with diffuse anterior scleritis (17.5%), necrotising anterior scleritis (0%) or posterior scleritis (12.5%). Of the 13 patients with a positive TST, 6 patients were suspected of having tuberculosis as the cause of their scleritis (3 diffuse anterior, 2 nodular anterior, 0 necrotising anterior, 1 posterior). These six patients were initially unresponsive to topical corticosteroid treatment alone, and all had no other identifiable cause for their ocular inflammation. anti-tuberculosis treatment as per current WHO guidelines, 17 and all six patients experienced improvement within 1e2 months, and eventually full resolution of their scleritis after initiation of anti-tuberculosis treatment. In patient 1, the pleural effusion also resolved with anti-tuberculosis treatment. Topical corticosteroids were continued concomitantly, but systemic corticosteroids were not used in these patients. Diagnostic investigation revealed a systemic rheumatologic disorder in 18 patients (21.7%) as shown in table 2. The most common disorder was rheumatoid arthritis (9.6%), followed by relapsing polychondritis (3.6%), autoimmune thyroiditis (3.6%), ankylosing spondylitis (1.2%), systemic lupus erythematosus (1.2%), Wegener 's granulomatosis (1.2%) and vasculitis associated with anti-neutrophillic cytoplasmic antibody (1.2%). An associated rheumatologic disease was most common for patients with diffuse anterior scleritis (28.1%), followed by patients with necrotising anterior scleritis (25.0%). Systemic rheumatological disorders were not found in any of the patients with either nodular anterior scleritis or posterior scleritis.
Treatment modalities for all 83 study patients are shown in table 3. Inflammation was successfully controlled in 43 patients (51.8%) using topical corticosteroids alone. Thirty-five patients (42.2%) received systemic corticosteroid treatment, and 19 patients (22.9%) received an immunosuppressive agent. Oral NSAIDs were used in only five patients. There was a marked difference in the treatment required between types of scleritis. While 36 of 57 patients (63.1%) with diffuse anterior scleritis and 7 of 9 patients (77.8%) with nodular anterior scleritis were treated with topical corticosteroids alone, 7 of 8 patients (87.5%) with necrotising anterior scleritis and 8 of 9 patients (88.9%) with posterior scleritis received systemic corticosteroid treatment. The most common serious adverse effect of oral corticosteroid use was hyperglycaemia, observed in 4 of 35 patients (11.4%) treated with oral corticosteroids, while osteoporosis developed in 2 patients (5.7%).
An immunosuppressive agent was used in all 8 patients (100%) with necrotising anterior scleritis, and in 3 of 9 patients (33.3%) with posterior scleritis and 8 of 57 patients (14.0%) with diffuse anterior scleritis. Methotrexate was the most commonly utilised immunosuppressive agent, administered in 16 patients (19%), while azathioprine, ciclosporin or cyclophosphamide was used in 3 patients each. Of the 16 patients receiving methotrexate, 8 had diffuse anterior scleritis, 6 had necrotising anterior scleritis and 2 had posterior scleritis. The median initial dose of methotrexate was 4 mg weekly (range 2e7.5 mg) and the median maximum dose was 6 mg (range 6e12 mg) weekly. The median duration of methotrexate treatment was 32 months (range 1e117 months). Methotrexate was discontinued in three patients due to the adverse effects of reversible leukopenia, elevated liver enzymes and facial cellulitis in one patient each; these patients discontinued their methotrexate treatment at 1, 2.5 and 5 months, respectively. The 13 patients who were able to continue on methotrexate treatment without adverse effects received methotrexate for at least 10 months. Of these 13 patients, control of inflammation according to our defined criteria was obtained in 12 patients (92.3%) with the concomitant systemic corticosteroid dose markedly reduced as shown in table 4. Furthermore, three of these patients continued to be in remission of disease for at least 13 months after stopping methotrexate, including two patients with diffuse anterior scleritis and one patient with necrotising anterior scleritis. Table 5 shows the best-corrected visual acuity at specific follow-up intervals for all patients in whom these data were available. Patients with diffuse anterior or nodular anterior scleritis had the best visual outcomes, with over 90% of eyes with a visual acuity of 0.5 or better, and this percentage remained essentially unchanged during the follow-up period. Patients with posterior scleritis also had generally good visual outcomes. However, 10e30% of patients with necrotising scleritis had a visual acuity of 0.1 or worse at sometime during their follow-up.
DISCUSSION
Previous series from North America and Europe have demonstrated that systemic autoimmune diseases are present in approximately 40e50% of patients with scleritis. 3e5 In our series, 18 patients (22%) had a systemic rheumatologic disease. The most common rheumatologic disease was rheumatoid arthritis, with other disorders including relapsing polychondritis, autoimmune thyroiditis, ankylosing spondylitis, systemic lupus erythematosus, Wegener's granulomatosis and vasculitis associated with anti-neutrophillic cytoplasmic antibody. In two Japanese case series of scleritis, the percentage of patients that had systemic rheumatologic disease was roughly 15% in both studies. 18 19 Taken together with our findings, this suggests the possibility that association of systemic diseases might be lower in Japanese patients with scleritis compared to North American and European populations.
In the present study, roughly 50% of patients responded to topical corticosteroids alone; however, 42% required systemic corticosteroid treatment and 23% required the use of systemic immunosuppressive drugs. Use of immunosuppressive agents was particularly high in patients with necrotising scleritis and posterior scleritis (100% and 33%, respectively). As has also been reported previously in Japanese patients, 18 necrotising scleritis and posterior scleritis required more aggressive medical treatment in our study.
Scleral inflammation was controlled in 92.3% of the patients who received methotrexate treatment and were able to continue this treatment without discontinuation due to adverse effects. The series by Jachens and Chu 20 reported that inflammation control was achieved in 11 of 18 patients with non-necrotising scleritis using methotrexate. In their study, the dose of methotrexate ranged from 7.5 to 35 mg weekly. In contrast, in the present study, the maximum dose of methotrexate ranged from 6 to 12 mg weekly, with a successful corticosteroid-sparing effect achieved in 10 (90.9%) of the 11 patients who were receiving methotrexate concomitantly with systemic prednisolone. All patients who received systemic treatment with corticosteroids and/or immunosuppressive agents in our series achieved good control of their inflammation. Direct comparison between the two studies is impossible because of differences in ethnicity and clinical characteristics of the patient populations. However, our data appear to indicate that lower doses of methotrexate may be sufficient as a corticosteroid-sparing agent in Japanese scleritis patients.
The present study demonstrated that, although some patients with necrotising scleritis had poorer visual outcomes during the follow-up period, the visual prognosis in the majority of patients was quite good, especially for eyes with diffuse anterior or nodular anterior scleritis. In one series at another Japanese institution, 90% of eyes with scleritis had a visual acuity of 20/ 40 or better at last visit. 19 Jabs and colleagues 10 reported that 36% of patients with rheumatologic disease had a decrease in visual acuity and roughly 40% of all patients with scleritis had some systemic rheumatologic disease, suggesting that the presence of an underlying systemic disease might be associated with visual loss and more severe disease in scleritis. In our series, only 22% of patients with scleritis had an underlying systemic rheumatologic disease. Thus, it may be that a lower proportion of associated systemic rheumatologic disease in Japanese patients with scleritis is related to the relatively good visual outcomes.
In the present study, 13 of 63 patients (20.6%) who received TST had a positive result, the TST positive rate being higher in patients with nodular scleritis (55.5%) than in patients with diffuse anterior scleritis (17.5%), necrotising anterior scleritis (0%) or posterior scleritis (12.5%). Six of these 13 patients received treatment with anti-tuberculosis treatment without systemic corticosteroids, and experienced total resolution of their scleritis. We presumed that tuberculosis was the cause of the scleritis in these patients because of the absence of other causes and the time sequence of resolution within months of starting anti-tuberculosis treatment, although we cannot rule out spontaneous resolution. Tabbara 21 has suggested that tuberculosis might be involved in the pathogenesis of scleritis in some patients, particularly in eyes that present with localised elevated nodules of the sclera. Recently, we reported that the 
